The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Wegovy, a brand name for semaglutide, is a GLP-1 inhibitor medication that targets the parts of the brain that regulate ...

The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...